{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:05:41Z","timestamp":1761491141739,"version":"3.44.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T00:00:00Z","timestamp":1644105600000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ando.2020.12.003","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T11:44:23Z","timestamp":1606995863000},"page":"52-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Medical management of adrenocortical carcinoma: Current recommendations, new therapeutic options and future perspectives"],"prefix":"10.1016","volume":"82","author":[{"given":"Vincent","family":"Amodru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Eve","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Libe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Brue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Reznik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Castinetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2020.12.003_bib0345","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1210\/jc.2013-3020","article-title":"Update in adrenocortical carcinoma","volume":"98","author":"Fassnacht","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.003_bib0350","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1530\/EJE-13-0142","article-title":"Surgery for adrenocortical carcinoma in The Netherlands: analysis of the national cancer registry data","volume":"169","author":"Kerkhofs","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2020.12.003_bib0355","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrendo.2010.235","article-title":"Adrenocortical carcinoma: a clinician's update","volume":"7","author":"Fassnacht","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2020.12.003_bib0360","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2020.12.003_bib0365","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncr.24030","article-title":"Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification","volume":"115","author":"Fassnacht","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2020.12.003_bib0370","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): a European Network for the Study of Adrenal Tumor (ENSAT) study","volume":"26","author":"Lib\u00e9","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2020.12.003_bib0375","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors","volume":"113","author":"Bilimoria","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2020.12.003_bib0380","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2014-3182","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","author":"Beuschlein","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.003_bib0385","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assi\u00e9","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.ando.2020.12.003_bib0390","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1210\/jc.2018-01348","article-title":"Targeted molecular analysis in adrenocortical carcinomas: a strategy toward improved personalized prognostication","volume":"103","author":"Lippert","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.003_bib0395","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1210\/jc.2010-0803","article-title":"Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers","volume":"95","author":"Fassnacht","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.003_bib0400","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1245\/s10434-015-4810-y","article-title":"Curative resection of adrenocortical carcinoma: rates and patterns of postoperative recurrence","volume":"23","author":"Amini","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ando.2020.12.003_bib0405","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa293","article-title":"Expression of SOAT1 in adrenocortical carcinoma and response to mitotane monotherapy: an ENSAT multicenter study","volume":"105","author":"Weigand","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.003_bib0410","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2020.12.003_bib0415","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2020.12.003_bib0420","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1210\/jc.2017-02591","article-title":"Mitotane monotherapy in patients with advanced adrenocortical carcinoma","volume":"103","author":"Megerle","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.003_bib0425","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2020.12.003_bib0430","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/bjc.2013.229","article-title":"Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study","volume":"108","author":"Urup","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ando.2020.12.003_bib0435","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1210\/jc.2017-01624","article-title":"Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors","volume":"102","author":"Henning","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.003_bib0440","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040941","article-title":"Efficacy of the EDP-M scheme plus adjunctive surgery in the management of patients with advanced adrenocortical carcinoma: the Brescia Experience","volume":"12","author":"Lagan\u00e0","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ando.2020.12.003_bib0445","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1530\/EJE-19-0570","article-title":"Activity and safety of temozolomide in advanced adrenocortical carcinoma patients","volume":"181","author":"Cosentini","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2020.12.003_bib0450","article-title":"Analysis of adjuvant chemotherapy in patients undergoing curative-intent resection of localized adrenocortical carcinoma","author":"Al Asadi","year":"2020","journal-title":"Am J Surg"},{"key":"10.1016\/j.ando.2020.12.003_bib0455","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1530\/ERC-11-0337","article-title":"Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models","volume":"19","author":"Mariniello","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2020.12.003_bib0460","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fendo.2011.00027","article-title":"Sunitinib inhibits cell proliferation and alters steroidogenesis by down-regulation of HSD3B2 in adrenocortical carcinoma cells","volume":"2","author":"Kroiss","year":"2011","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ando.2020.12.003_bib0465","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-11-0918","article-title":"Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma","volume":"166","author":"Berruti","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2020.12.003_bib0470","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.003_bib0475","first-page":"105","article-title":"Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib","author":"Kroiss","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.003_bib0480","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1210\/jc.2013-2165","article-title":"Molecular screening for a personalized treatment approach in advanced adrenocortical cancer","volume":"98","author":"De Martino","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.003_bib0485","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/1078-0432.CCR-08-1067","article-title":"Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling","volume":"15","author":"Giordano","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ando.2020.12.003_bib0490","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/bjc.2017.330","article-title":"A phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours","volume":"117","author":"Papadopoulos","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ando.2020.12.003_bib0495","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/modpathol.2010.153","article-title":"Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome","volume":"23","author":"Adam","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ando.2020.12.003_bib0500","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bcp.2015.10.012","article-title":"Inhibition of epithelial growth factor receptor can play an important role in reducing cell growth and survival in adrenocortical tumors","volume":"98","author":"Gagliano","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ando.2020.12.003_bib0505","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1210\/jc.2007-2564","article-title":"Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine","volume":"93","author":"Quinkler","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.003_bib0510","first-page":"43","article-title":"The role of insulin-like growth factor system in the adrenocortical tumors","volume":"44","author":"Altieri","year":"2019","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.ando.2020.12.003_bib0515","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12020-019-01869-1","article-title":"IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer","volume":"64","author":"De Martino","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2020.12.003_bib0520","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1210\/jc.2008-1456","article-title":"Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma","volume":"94","author":"Barlaskar","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.003_bib0525","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1210\/jc.2008-0065","article-title":"Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors","volume":"93","author":"Almeida","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.003_bib0530","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2020.12.003_bib0535","doi-asserted-by":"crossref","first-page":"49636","DOI":"10.18632\/oncotarget.10421","article-title":"Metformin as a new anti-cancer drug in adrenocortical carcinoma","volume":"7","author":"Poli","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ando.2020.12.003_bib0540","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.1158\/1078-0432.CCR-10-2979","article-title":"Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer","volume":"17","author":"Naing","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ando.2020.12.003_bib0545","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s10637-013-0013-1","article-title":"Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer","volume":"31","author":"Ganesan","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ando.2020.12.003_bib0550","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10637-020-00899-1","article-title":"A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma","volume":"38","author":"Smith","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ando.2020.12.003_bib0555","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ando.2020.12.003_bib0560","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2020.12.003_bib0565","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1210\/jc.2019-00600","article-title":"Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial","volume":"104","author":"Carneiro","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.003_bib0570","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001009","article-title":"Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma","volume":"8","author":"Bedrose","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ando.2020.12.003_bib0575","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ando.2020.12.003_bib0580","first-page":"8","article-title":"Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma","author":"Landwehr","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ando.2020.12.003_bib0585","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"29","author":"Zheng","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ando.2020.12.003_bib0590","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41574-019-0221-7","article-title":"Adrenocortical carcinoma\u00a0\u2013\u00a0towards genomics guided clinical care","volume":"15","author":"Crona","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2020.12.003_bib0595","doi-asserted-by":"crossref","first-page":"101434","DOI":"10.1016\/j.beem.2020.101434","article-title":"Next-generation therapies for adrenocortical carcinoma","volume":"34","author":"Altieri","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.003_bib0600","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1038\/s41388-020-1358-5","article-title":"Wnt\/\u03b2-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice","volume":"39","author":"Borges","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.ando.2020.12.003_bib0605","doi-asserted-by":"crossref","first-page":"43016","DOI":"10.18632\/oncotarget.5513","article-title":"Inhibition of the Tcf\/beta-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis","volume":"6","author":"Leal","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ando.2020.12.003_bib0610","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1101\/gad.317412.118","article-title":"A ZNRF3-dependent Wnt\/\u03b2-catenin signaling gradient is required for adrenal homeostasis","volume":"33","author":"Basham","year":"2019","journal-title":"Genes Dev"},{"key":"10.1016\/j.ando.2020.12.003_bib0615","doi-asserted-by":"crossref","first-page":"22825","DOI":"10.18632\/oncotarget.15221","article-title":"Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ando.2020.12.003_bib0620","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/jclinpath-2014-202514","article-title":"Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies","volume":"67","author":"Ross","year":"2014","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ando.2020.12.003_bib0625","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3389\/fendo.2020.00219","article-title":"Targeted gene expression profile reveals CDK4 as therapeutic target for selected patients with adrenocortical carcinoma","volume":"11","author":"Liang","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ando.2020.12.003_bib0630","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.18632\/aging.101356","article-title":"A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas","volume":"9","author":"Hadjadj","year":"2017","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.ando.2020.12.003_bib0635","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12020-017-1270-0","article-title":"Palbociclib inhibits proliferation of human adrenocortical tumor cells","volume":"59","author":"Fiorentini","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2020.12.003_bib0640","doi-asserted-by":"crossref","first-page":"e73959","DOI":"10.1371\/journal.pone.0073959","article-title":"Single nucleotide polymorphism array profiling of adrenocortical tumors\u00a0\u2013\u00a0evidence for an adenoma carcinoma sequence?","volume":"8","author":"Ronchi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ando.2020.12.003_bib0645","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/ERC-15-0163","article-title":"Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome","volume":"22","author":"Ronchi","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2020.12.003_bib0650","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/bjc.2017.495","article-title":"A phase I trial of the \u03b3-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma","volume":"118","author":"Cook","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ando.2020.12.003_bib0655","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/jcb.27451","article-title":"MAPK\/ERK pathway inhibition is a promising treatment target for adrenocortical tumors","volume":"120","author":"Pereira","year":"2019","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ando.2020.12.003_bib0660","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1677\/ERC-08-0101","article-title":"Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas","volume":"16","author":"Kotoula","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2020.12.003_bib0665","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.2147\/CMAR.S169558","article-title":"The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials","volume":"10","author":"Guo","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ando.2020.12.003_bib0670","first-page":"105","article-title":"Treatment with 90Y\/177Lu-DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors","author":"Grisanti","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.003_bib0675","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1530\/JOE-12-0297","article-title":"Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor","volume":"216","author":"Takeshita","year":"2013","journal-title":"J Endocrinol"},{"key":"10.1016\/j.ando.2020.12.003_bib0680","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","article-title":"Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma","volume":"75","author":"Kroiss","year":"2011","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000342662031307X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000342662031307X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:52:56Z","timestamp":1757717576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000342662031307X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S000342662031307X"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2020.12.003","relation":{},"ISSN":["0003-4266"],"issn-type":[{"type":"print","value":"0003-4266"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical management of adrenocortical carcinoma: Current recommendations, new therapeutic options and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2020.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}